Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07200167

Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom-01B)

single-center, randomized, cross over, double-blind, placebo controlled intervention study

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

24 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CMS - Center za motnje spanja

Ljubljana, 1000, Slovenia

Location contact

Barbara Gnidovec Stražišar

CONTACT

[email protected]

+386 590 68 70

Barbara Gnidovec Stražišar

PRINCIPAL_INVESTIGATOR

About this study

The single-center, randomized, cross over, double-blind, placebo controlled intervention study will include 70 subjects who will test the efficacy of three formulations on sleep quality parameters.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subject Informed consent form (ICF) is signed
  • aged 24-65 years at the time of the signature of ICF
  • suboptimal sleep quality according to Pittsburgh Sleep Quality Index (PSQI-SI): PSQI > 5
  • no clinically significant (subthreshold) insomnia according to Pittsburgh Sleep Quality Index (PSQI-SI) (Kmetec et al., 2022): PSQI <= 9
  • a body mass index (BMI) <= 32 kg/m2
  • stable medications for non excluded concurrent medical conditions for six weeks prior to the screening visit
  • ability to ingest oral food supplement (study product)
  • willing to follow all study procedures, including attending all site visits and use of actigraphy

Exclusion criteria

  • diagnosed or subject to therapy due to sleep disorders
  • acute infectious disease
  • any kind of chronic pharmacological therapy with antihypertensives or antidepressants
  • any kind of other pharmacological therapy that could interact with active ingredients used in the study
  • pregnancy or planned pregnancy, lactation, menopause (with pharmacological treatment)
  • use of beta-blockers
  • chronic use of use of prostaglandin synthesis inhibitors (nonsteroidal anti-inflammatory drugs), such as acetylsalicylic acid and ibuprofen
  • supplementation with melatonin or other food supplements intendent for sleep quality during last 2 weeks
  • unwillingness to maintain caffeine abstinence after 4:00 PM during the study
  • not having a mobile upper extremity for attaching an actigraph
  • known alcohol and/or drug abuse
  • unwillingness to comply with the maximum limit of 2 alcoholic drinks per day, and only up to 1 alcoholic drink after 6:00 PM during the study
  • known lactose/gluten intolerances/food allergies
  • known gastrointestinal disease
  • less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
  • have stomach or bowel resection
  • night work or work shifts with night work
  • mental incapacity that precludes adequate understanding or cooperation
  • participation in another investigational study

Treatment and study plan

21 days of intervention with Placebo Product (PP)

Dietary Supplement

1 capsule (placebo)

21 days of intervention with Active Control (AC)

Dietary Supplement

1 capsule (melatonin)

21 days of intervention with Test Product (TP)

Dietary Supplement

1 capsule (valerian root extract)

Primary outcomes

  1. Difference in sleep onset latency (SOL) compared to placebo

    Time frame: 2 weeks

    Difference in sleep onset latency (SOL) compared to placebo assessed by actigraphy.

  2. Difference in sleep quality compared to placebo

    Time frame: 2 weeks

    Difference in sleep quality compared to placebo - assessed by adapted Pittsburgh Sleep Quality Index (PSQI; ranking from 0 [best] to 21 [worst])

Secondary outcomes

  1. Difference in sleep efficiency (SE) compared to placebo

    Time frame: 2 weeks

    Difference in sleep efficiency (SE) compared to placebo - assessed by actigraphy

Other outcomes

  1. Difference in sleep onset latency (SOL) compared to placebo

    Time frame: 3 weeks

    Difference in sleep onset latency (SOL) compared to placebo assessed by actigraphy.

  2. Difference in sleep efficiency (SE) compared to placebo

    Time frame: 3 weeks

    Difference in sleep efficiency (SE) compared to placebo - assessed by actigraphy

Study contacts

Contact information is provided by the study sponsor or research team.

Igor Pravst, PhD

CONTACT

[email protected]

+386 590 68871

Sponsors and collaborators

Lead sponsor

Institute of Nutrition, Slovenia (Nutris)

Other

Collaborators

  • CMS - Center za motnje spanja, Ljubljana, Slovenia
  • Faculty of Pharmacy, University of Ljubljana, Slovenia
  • Faculty of health sciences, Celje, Slovenia
  • Valens Int. d.o.o., Slovenija

Registry information

Official study title

Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom Study B)

Acronym: NutriSom-01B

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 30, 2025
Registry last updated
Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.